Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series

Adults with sickle cell disease can develop pulmonary hypertension from a multitude of etiologies. Classified as WHO Group 5, there are no therapies approved for the treatment of sickle cell disease-pulmonary hypertension. Thromboembolic disease is prevalent in sickle cell disease and can lead to pu...

Descripción completa

Detalles Bibliográficos
Autores principales: Weir, Nargues A., Conrey, Anna, Lewis, Denise, Mehari, Alem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083805/
https://www.ncbi.nlm.nih.gov/pubmed/30033820
http://dx.doi.org/10.1177/2045894018791802
_version_ 1783346052676452352
author Weir, Nargues A.
Conrey, Anna
Lewis, Denise
Mehari, Alem
author_facet Weir, Nargues A.
Conrey, Anna
Lewis, Denise
Mehari, Alem
author_sort Weir, Nargues A.
collection PubMed
description Adults with sickle cell disease can develop pulmonary hypertension from a multitude of etiologies. Classified as WHO Group 5, there are no therapies approved for the treatment of sickle cell disease-pulmonary hypertension. Thromboembolic disease is prevalent in sickle cell disease and can lead to pulmonary hypertension. The only approved medical therapy for chronic thromboembolic pulmonary hypertension is riociguat. We report the experience, safety and tolerability of riociguat use in a series of sickle cell disease patients with chronic thromboembolic pulmonary hypertension.
format Online
Article
Text
id pubmed-6083805
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60838052018-08-14 Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series Weir, Nargues A. Conrey, Anna Lewis, Denise Mehari, Alem Pulm Circ Case Report Adults with sickle cell disease can develop pulmonary hypertension from a multitude of etiologies. Classified as WHO Group 5, there are no therapies approved for the treatment of sickle cell disease-pulmonary hypertension. Thromboembolic disease is prevalent in sickle cell disease and can lead to pulmonary hypertension. The only approved medical therapy for chronic thromboembolic pulmonary hypertension is riociguat. We report the experience, safety and tolerability of riociguat use in a series of sickle cell disease patients with chronic thromboembolic pulmonary hypertension. SAGE Publications 2018-07-23 /pmc/articles/PMC6083805/ /pubmed/30033820 http://dx.doi.org/10.1177/2045894018791802 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Weir, Nargues A.
Conrey, Anna
Lewis, Denise
Mehari, Alem
Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
title Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
title_full Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
title_fullStr Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
title_full_unstemmed Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
title_short Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
title_sort riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083805/
https://www.ncbi.nlm.nih.gov/pubmed/30033820
http://dx.doi.org/10.1177/2045894018791802
work_keys_str_mv AT weirnarguesa riociguatuseinsicklecellrelatedchronicthromboembolicpulmonaryhypertensionacaseseries
AT conreyanna riociguatuseinsicklecellrelatedchronicthromboembolicpulmonaryhypertensionacaseseries
AT lewisdenise riociguatuseinsicklecellrelatedchronicthromboembolicpulmonaryhypertensionacaseseries
AT meharialem riociguatuseinsicklecellrelatedchronicthromboembolicpulmonaryhypertensionacaseseries

Ejemplares similares